Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data

Niedzica Camacho(Memorial Sloan Kettering Cancer Center), Peter Van Loo(The Francis Crick Institute), Sandra E. Edwards(Institute of Cancer Research), Jonathan D. Kay(Cancer Research UK Cambridge Center), Lucy Matthews(Institute of Cancer Research), Kerstin Haase(The Francis Crick Institute), Jeremy Clark(University of East Anglia), Nening M. Dennis(Royal Marsden NHS Foundation Trust), Sarah Thomas(Royal Marsden NHS Foundation Trust), Bárbara Kremeyer(Wellcome Sanger Institute), Jorge Zamora(Wellcome Sanger Institute), Adam P. Butler(Wellcome Sanger Institute), Gunes Gundem(Memorial Sloan Kettering Cancer Center), Sue Merson(Institute of Cancer Research), Hayley J. Luxton(Cancer Research UK Cambridge Center), Steve Hawkins(Cancer Research UK Cambridge Center), Mohammed Ghori(Wellcome Sanger Institute), Luke Marsden(University of Oxford), Adam Lambert(CRUK/MRC Oxford Institute for Radiation Oncology), Katalin Karászi(University of Oxford), Gill Pelvender(University of Oxford), Charles Massie(Cancer Research UK Cambridge Center), Zsofia Kote‐Jarai(Institute of Cancer Research), Keiran Raine(Wellcome Sanger Institute), David Jones(Wellcome Sanger Institute), William Howat(Cancer Research UK Cambridge Center), Steven Hazell(Royal Marsden NHS Foundation Trust), Naomi Livni(Royal Marsden NHS Foundation Trust), Cyril Fisher(Royal Marsden NHS Foundation Trust), Christopher Ogden(Royal Marsden NHS Foundation Trust), Pardeep Kumar(Royal Marsden NHS Foundation Trust), Alan Thompson(Royal Marsden NHS Foundation Trust), David Nicol(Royal Marsden NHS Foundation Trust), Erik Mayer(Royal Marsden NHS Foundation Trust), Tim Dudderidge(Royal Marsden NHS Foundation Trust), Yongwei Yu(Second Military Medical University), Hongwei Zhang(Second Military Medical University), Nimish Shah(Cambridge University Hospitals NHS Foundation Trust), Vincent J. Gnanapragasam(University of Cambridge), The CRUK-ICGC Prostate Group(Johns Hopkins University), William B. Isaacs(Johns Hopkins University), Tapio Visakorpi(University of Oxford), Freddie C. Hamdy(Queen Mary University of London), Daniel M. Berney(Queen Mary University of London), Clare Verrill(Cambridge University Hospitals NHS Foundation Trust), Anne Y. Warren(Centre for Human Genetics), David C. Wedge(Centre for Human Genetics), Andy G. Lynch(University of St Andrews), Christopher S. Foster(Queen Mary University of London), Yong‐Jie Lu(Queen Mary University of London), G. Steven Bova(Cancer Research UK Cambridge Center), Hayley C. Whitaker(Wellcome Sanger Institute), Ultan McDermott(University of Cambridge), David E. Neal(Royal Marsden NHS Foundation Trust), Rosalind Eeles(University of East Anglia), Colin S. Cooper(University of East Anglia), Daniel S. Brewer(University of East Anglia)
PLoS Genetics
September 25, 2017
Cited by 43Open Access
Full Text

Abstract

A variety of models have been proposed to explain regions of recurrent somatic copy number alteration (SCNA) in human cancer. Our study employs Whole Genome DNA Sequence (WGS) data from tumor samples (n = 103) to comprehensively assess the role of the Knudson two hit genetic model in SCNA generation in prostate cancer. 64 recurrent regions of loss and gain were detected, of which 28 were novel, including regions of loss with more than 15% frequency at Chr4p15.2-p15.1 (15.53%), Chr6q27 (16.50%) and Chr18q12.3 (17.48%). Comprehensive mutation screens of genes, lincRNA encoding sequences, control regions and conserved domains within SCNAs demonstrated that a two-hit genetic model was supported in only a minor proportion of recurrent SCNA losses examined (15/40). We found that recurrent breakpoints and regions of inversion often occur within Knudson model SCNAs, leading to the identification of ZNF292 as a target gene for the deletion at 6q14.3-q15 and NKX3.1 as a two-hit target at 8p21.3-p21.2. The importance of alterations of lincRNA sequences was illustrated by the identification of a novel mutational hotspot at the KCCAT42, FENDRR, CAT1886 and STCAT2 loci at the 16q23.1-q24.3 loss. Our data confirm that the burden of SCNAs is predictive of biochemical recurrence, define nine individual regions that are associated with relapse, and highlight the possible importance of ion channel and G-protein coupled-receptor (GPCR) pathways in cancer development. We concluded that a two-hit genetic model accounts for about one third of SCNA indicating that mechanisms, such haploinsufficiency and epigenetic inactivation, account for the remaining SCNA losses.


Related Papers

No related papers found

Powered by citation graph analysis